Siren Morken
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Siren Morken has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Lene Weber Vestermark
Department of Oncology University Hospital of Southern Denmark Esbjerg Denmark
6 shared publicationsAurel Perren
Institute of Tissue Medicine and Pathology, University of Bern 6
5 shared publicationsPer Pfeiffer
Department of Oncology Odense University Hospital Odense Denmark
5 shared publicationsAnna Sundlöv
Division of Oncology, Department of Clinical Sciences Lund Lund University Lund Sweden
4 shared publicationsAnne Couvelard
Department of Pathology Bichat Hospital AP‐HP and Paris Cité University Paris France
4 shared publicationsChristian Kersten
Department of Research Hospital of Southern Norway Kristiansand Norway
4 shared publications
Latest Publications
- Open Access
- 18 October 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (10) , e70296
Genetic intratumour heterogeneity in digestive high‐grade neuroendocrine neoplasms
Digestive high‐grade neuroendocrine neoplasms (HG‐NEN) are rare and heterogeneous tumours with an aggressive biology and limited treatment efficacy. Genetic intratumour heterogeneity (ITH) is a mechanism of progression and treatment resistance in other cancers, yet unexplored in digestive HG‐NEN. Next‐generation sequencing with a 360‐cancer gene panel was performed on 51 digestive HG‐NEN, suitable for multiregional sampling. The mutational status of each sample within a patient was assessed to calculate an ITH‐index, defined as the average number of discordant mutations across all pair‐wise comparisons between samples. An ITH‐index based on primary tumour samples was calculated for chemotherapy‐naïve cases: 28 neuroendocrine carcinomas (NEC), 9 mixed neuroendocrine‐non‐neuroendocrine neoplasms (MiNEN) and 3 neuroendocrine tumour grade 3 (NET G3). Median ITH‐index in NEC/MiNEN was 5, with a wide range (0–98.8). Greater heterogeneity was associated with right‐sided colonic primaries ( p = .005) and higher tumour mutational burden ( r = 0.74, p < .001). Median overall survival was 7 months longer in NEC/MiNEN with median ITH‐index above compared to below median (22.5 vs. 15.5 months, p = .077), driven mostly by patients with locoregional disease. Response to first‐line chemotherapy was not influenced by median ITH‐index. No heterogeneity was found among driver mutations in BRAF and KRAS . NET G3 displayed low heterogeneity (ITH‐index 2–3). Higher ITH‐index was not associated with shorter survival or treatment response, suggesting that genetic ITH is not the primary resistance mechanism in digestive NEC/MiNEN. Moving towards targeted treatment strategies, our data indicate that a single biopsy may underestimate ITH. BRAF and KRAS may be favourable targets as they displayed no heterogeneity.
- 18 October 2026
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 38 (10) , e70296
Open AccessGenetic intratumour heterogeneity in digestive high‐grade neuroendocrine neoplasms
Digestive high‐grade neuroendocrine neoplasms (HG‐NEN) are rare and heterogeneous tumours with an aggressive biology and limited treatment efficacy. Genetic intratumour heterogeneity (ITH) is a mechanism of progression and treatment resistance in other cancers, yet unexplored in digestive HG‐NEN. Next‐generation sequencing with a 360‐cancer gene panel was performed on 51 digestive HG‐NEN, suitable for multiregional sampling. The mutational status of each sample within a patient was assessed to calculate an ITH‐index, defined as the average number of discordant mutations across all pair‐wise comparisons between samples. An ITH‐index based on primary tumour samples was calculated for chemotherapy‐naïve cases: 28 neuroendocrine carcinomas (NEC), 9 mixed neuroendocrine‐non‐neuroendocrine neoplasms (MiNEN) and 3 neuroendocrine tumour grade 3 (NET G3). Median ITH‐index in NEC/MiNEN was 5, with a wide range (0–98.8). Greater heterogeneity was associated with right‐sided colonic primaries ( p = .005) and higher tumour mutational burden ( r = 0.74, p < .001). Median overall survival was 7 months longer in NEC/MiNEN with median ITH‐index above compared to below median (22.5 vs. 15.5 months, p = .077), driven mostly by patients with locoregional disease. Response to first‐line chemotherapy was not influenced by median ITH‐index. No heterogeneity was found among driver mutations in BRAF and KRAS . NET G3 displayed low heterogeneity (ITH‐index 2–3). Higher ITH‐index was not associated with shorter survival or treatment response, suggesting that genetic ITH is not the primary resistance mechanism in digestive NEC/MiNEN. Moving towards targeted treatment strategies, our data indicate that a single biopsy may underestimate ITH. BRAF and KRAS may be favourable targets as they displayed no heterogeneity.
- Open Access
- 1 July 2026
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 33 (7)
Origin and evolution of colorectal mixed neuroendocrine–non-neuroendocrine neoplasms (MiNEN)
Graphical Colorectal neuroendocrine carcinoma (NEC) is a rare and aggressive cancer and in a subset of patients associated with an adenocarcinoma (AC) component. When both components exceed 30% of the tumour, it is classified as mixed neuroendocrine–non-neuroendocrine neoplasm (MiNEN), although there is an ongoing debate about whether any presence of two distinct components should be sufficient for a MiNEN diagnosis. This study aimed to investigate the origin and subsequent genetic changes of these two components. Ten colorectal cases suitable for sampling of an AC and a poorly differentiated NEC component were identified from the NORDIC NEC 2 study and sequenced across a 360-cancer gene panel. Mock phylogenetic trees were constructed from the molecular profiles of each sample within a patient. All ten cases revealed a common trunk of shared somatic mutations, including well-known colorectal cancer driver mutations such as BRAF, KRAS, APC, and TP53. In all cases, a single branching point separated the AC and NEC components. Private AC and NEC mutations generally had low variant allele frequencies, indicating that most AC and NEC cells were genetically similar. NEC, when compared with AC samples, demonstrated a higher frequency of private mutations (P = 0.009), indicating a higher mutation rate and greater ploidy (P = 0.012), suggesting an association between genomic duplication and AC-to-NEC transition. Shared mutations indicate a common clonal origin, underscoring the role of established colorectal driver mutations in the early development of these tumours, while the mechanisms underlying NEC differentiation remain poorly understood and may involve non-genetic factors.
- 1 July 2026
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 33 (7)
Open AccessOrigin and evolution of colorectal mixed neuroendocrine–non-neuroendocrine neoplasms (MiNEN)
Graphical Colorectal neuroendocrine carcinoma (NEC) is a rare and aggressive cancer and in a subset of patients associated with an adenocarcinoma (AC) component. When both components exceed 30% of the tumour, it is classified as mixed neuroendocrine–non-neuroendocrine neoplasm (MiNEN), although there is an ongoing debate about whether any presence of two distinct components should be sufficient for a MiNEN diagnosis. This study aimed to investigate the origin and subsequent genetic changes of these two components. Ten colorectal cases suitable for sampling of an AC and a poorly differentiated NEC component were identified from the NORDIC NEC 2 study and sequenced across a 360-cancer gene panel. Mock phylogenetic trees were constructed from the molecular profiles of each sample within a patient. All ten cases revealed a common trunk of shared somatic mutations, including well-known colorectal cancer driver mutations such as BRAF, KRAS, APC, and TP53. In all cases, a single branching point separated the AC and NEC components. Private AC and NEC mutations generally had low variant allele frequencies, indicating that most AC and NEC cells were genetically similar. NEC, when compared with AC samples, demonstrated a higher frequency of private mutations (P = 0.009), indicating a higher mutation rate and greater ploidy (P = 0.012), suggesting an association between genomic duplication and AC-to-NEC transition. Shared mutations indicate a common clonal origin, underscoring the role of established colorectal driver mutations in the early development of these tumours, while the mechanisms underlying NEC differentiation remain poorly understood and may involve non-genetic factors.
- Open Access
- 5 February 2026
- Published by Wiley in International Journal of Cancer
- Vol. 158 (12) , 3217-3231
Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas
There is limited data regarding the rare and aggressive colorectal neuroendocrine carcinoma (CR‐NEC). In this large prospective study, molecular–clinical characteristics and treatment outcomes following palliative chemotherapy are reported for 163 metastatic CR‐NEC patients, with a comparison to a population‐based prospective cohort of 263 metastatic colorectal adenocarcinoma (CR‐AC) patients. Eighty‐three percent of CR‐NEC received first‐line platinum‐etoposide, while 98% of CR‐AC patients received first‐line fluorouracil‐based chemotherapy. Disease control rate across all first‐line regimens in CR‐NEC and CR‐AC was 43% vs. 74%, immediate progressive disease 46% vs. 15%, progression‐free survival 2.4 months (m) (95% CI 2.1–3.3) vs. 7.7 m (95% CI 6.9–8.5), and overall survival 6.7 m (95% CI 5.6–8.8) vs. 16.8 m (95% CI 13.7–20.3), all, p < .001. CR‐NEC more often had synchronous metastases, worse performance status, and symptom burden at treatment initiation than CR‐AC (all, p < .001). Two‐year survival was 9% vs. 37% in CR‐NEC and CR‐AC ( p < .001). BRAF mutations were frequent in CR‐NEC and CR‐AC (26% vs. 20%, p = .153) and associated with shorter OS in CR‐NEC and CR‐AC ( p = .025 and p = .003). KRAS mutations were less frequent in CR‐NEC than CR‐AC (34% vs. 45%, p = .041), but only associated with shorter OS in rectal NEC ( p = .04). The frequencies of APC and TP53 mutations were similar between the cohorts and did not impact survival. Metastatic CR‐NEC and CR‐AC are clinically distinct, with NEC demonstrating more aggressive features, limited treatment effect, and worse prognosis. Although they share important driver mutations, the underlying reason for their marked clinical differences remains unclear.
- 5 February 2026
- Published by Wiley in International Journal of Cancer
- Vol. 158 (12) , 3217-3231
Open AccessMolecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas
There is limited data regarding the rare and aggressive colorectal neuroendocrine carcinoma (CR‐NEC). In this large prospective study, molecular–clinical characteristics and treatment outcomes following palliative chemotherapy are reported for 163 metastatic CR‐NEC patients, with a comparison to a population‐based prospective cohort of 263 metastatic colorectal adenocarcinoma (CR‐AC) patients. Eighty‐three percent of CR‐NEC received first‐line platinum‐etoposide, while 98% of CR‐AC patients received first‐line fluorouracil‐based chemotherapy. Disease control rate across all first‐line regimens in CR‐NEC and CR‐AC was 43% vs. 74%, immediate progressive disease 46% vs. 15%, progression‐free survival 2.4 months (m) (95% CI 2.1–3.3) vs. 7.7 m (95% CI 6.9–8.5), and overall survival 6.7 m (95% CI 5.6–8.8) vs. 16.8 m (95% CI 13.7–20.3), all, p < .001. CR‐NEC more often had synchronous metastases, worse performance status, and symptom burden at treatment initiation than CR‐AC (all, p < .001). Two‐year survival was 9% vs. 37% in CR‐NEC and CR‐AC ( p < .001). BRAF mutations were frequent in CR‐NEC and CR‐AC (26% vs. 20%, p = .153) and associated with shorter OS in CR‐NEC and CR‐AC ( p = .025 and p = .003). KRAS mutations were less frequent in CR‐NEC than CR‐AC (34% vs. 45%, p = .041), but only associated with shorter OS in rectal NEC ( p = .04). The frequencies of APC and TP53 mutations were similar between the cohorts and did not impact survival. Metastatic CR‐NEC and CR‐AC are clinically distinct, with NEC demonstrating more aggressive features, limited treatment effect, and worse prognosis. Although they share important driver mutations, the underlying reason for their marked clinical differences remains unclear.
- Open Access
- 14 July 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 133 (3) , 420
Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study
- 14 July 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 133 (3) , 420
Open AccessCorrection: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study
- Top Cited PapersOpen Access
- 17 May 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 133 (3) , 316-324
Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study
Background: Digestive high-grade neuroendocrine neoplasms (HG-NEN) are rare and classified as neuroendocrine carcinomas (NEC) or neuroendocrine tumours G3 (NET G3), and differ in clinical and molecular characteristics, response to treatment and prognosis. Methods: Prospective multicenter study registering clinical data on patients with digestive HG-NEN. Treatment outcome in patients with advanced disease was compared after centralized pathological re-evaluation. Results: 427 NEC and 117 NET G3 received palliative chemotherapy. Immediate progression rate was 41% and 24%, progression-free survival (PFS) 3.4 m and 7.4 m, overall survival (OS) 7.4 m and 21.8 m for NEC and NET G3, respectively. Significant factors for OS in NEC were performance status (PS), Ki-67 > 55%, alkaline phosphatase (ALP), age, sex and for PFS colorectal primary and PS. NEC Ki-67 < 55% had similar OS comparing treatment. Significant factors for OS in NET G3 were platinum-based treatment, PS, age and ALP, and for PFS platinum-based treatment. Conclusions: Survival was shorter than expected in this unique population-based cohort of advanced digestive HG-NEN, likely due to inclusion of elderly and patients with poor PS. Several novel prognostic factors were identified for NEC and NET G3. An initial sub-effective platinum-based treatment for NET G3 could not be compensated by later-line treatment.
- 17 May 2025
- Published by Springer Nature in British Journal of Cancer
- Vol. 133 (3) , 316-324
Top Cited PapersOpen AccessCharacteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study
Background: Digestive high-grade neuroendocrine neoplasms (HG-NEN) are rare and classified as neuroendocrine carcinomas (NEC) or neuroendocrine tumours G3 (NET G3), and differ in clinical and molecular characteristics, response to treatment and prognosis. Methods: Prospective multicenter study registering clinical data on patients with digestive HG-NEN. Treatment outcome in patients with advanced disease was compared after centralized pathological re-evaluation. Results: 427 NEC and 117 NET G3 received palliative chemotherapy. Immediate progression rate was 41% and 24%, progression-free survival (PFS) 3.4 m and 7.4 m, overall survival (OS) 7.4 m and 21.8 m for NEC and NET G3, respectively. Significant factors for OS in NEC were performance status (PS), Ki-67 > 55%, alkaline phosphatase (ALP), age, sex and for PFS colorectal primary and PS. NEC Ki-67 < 55% had similar OS comparing treatment. Significant factors for OS in NET G3 were platinum-based treatment, PS, age and ALP, and for PFS platinum-based treatment. Conclusions: Survival was shorter than expected in this unique population-based cohort of advanced digestive HG-NEN, likely due to inclusion of elderly and patients with poor PS. Several novel prognostic factors were identified for NEC and NET G3. An initial sub-effective platinum-based treatment for NET G3 could not be compensated by later-line treatment.
- Open Access
- 23 October 2023
- Published by Springer Nature in British Journal of Cancer
- Vol. 129 (12) , 1930-1939
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
Background: The optimal treatment for metastatic high-grade gastroenteropancreatic (GEP) neuroendocrine neoplasms when Ki-67 ≤55% is unknown. A prospective multi-centre phase 2 study was performed to evaluate the efficacy and safety of everolimus and temozolomide as first-line treatment for these patients. Methods: Patients received everolimus 10 mg daily continuously and temozolomide 150 mg/m2 for 7 days every 2 weeks. Endpoints included response, survival, safety and quality of life (QoL). Histopathological re-evaluation according to the 2019 WHO classification was performed. Results: For 37 eligible patients, the primary endpoint with 65% disease control rate (DCR) at 6 months (m) was reached. The response rate was 30%, the median progression-free survival (PFS) 10.2 months and the median overall survival (OS) 26.4 months. Considering 26 NET G3 patients, 6 months DCR was 77% vs. 22% among nine NEC patients (p = 0.006). PFS was superior for NET G3 vs. NEC (12.6 months vs. 3.4 months, Log-rank-test: p = 0.133, Breslow-test: p < 0.001). OS was significantly better for NET G3 (31.4 months vs. 7.8 months, p = 0.003). Grade 3 and 4 toxicities were reported in 43% and 38%. QoL remained stable during treatment. Conclusion: Everolimus and temozolomide may be a treatment option for selected GEP-NET G3 patients including careful monitoring. Toxicity did not compromise QoL. Clinical trial registration: ClinicalTrials.gov (NTC02248012).
- 23 October 2023
- Published by Springer Nature in British Journal of Cancer
- Vol. 129 (12) , 1930-1939
Open AccessPhase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
Background: The optimal treatment for metastatic high-grade gastroenteropancreatic (GEP) neuroendocrine neoplasms when Ki-67 ≤55% is unknown. A prospective multi-centre phase 2 study was performed to evaluate the efficacy and safety of everolimus and temozolomide as first-line treatment for these patients. Methods: Patients received everolimus 10 mg daily continuously and temozolomide 150 mg/m2 for 7 days every 2 weeks. Endpoints included response, survival, safety and quality of life (QoL). Histopathological re-evaluation according to the 2019 WHO classification was performed. Results: For 37 eligible patients, the primary endpoint with 65% disease control rate (DCR) at 6 months (m) was reached. The response rate was 30%, the median progression-free survival (PFS) 10.2 months and the median overall survival (OS) 26.4 months. Considering 26 NET G3 patients, 6 months DCR was 77% vs. 22% among nine NEC patients (p = 0.006). PFS was superior for NET G3 vs. NEC (12.6 months vs. 3.4 months, Log-rank-test: p = 0.133, Breslow-test: p < 0.001). OS was significantly better for NET G3 (31.4 months vs. 7.8 months, p = 0.003). Grade 3 and 4 toxicities were reported in 43% and 38%. QoL remained stable during treatment. Conclusion: Everolimus and temozolomide may be a treatment option for selected GEP-NET G3 patients including careful monitoring. Toxicity did not compromise QoL. Clinical trial registration: ClinicalTrials.gov (NTC02248012).